Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.
Dorothy I JonesCharles E McGeeChristopher J SampleGregory D SempowskiDavid J PickupHerman F StaatsPublished in: Clinical and vaccine immunology : CVI (2016)
Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.
Keyphrases